Sun Pharma reveals new clinical data at the 2024 EADV Congress, showing significant improvements in severe skin conditions
Sun Pharmaceutical Industries Limited has made a significant breakthrough in the treatment of severe dermatological conditions, unveiling new clinical efficacy and safety data at the ... Read More
Sun Pharmaceutical bags LEQSELVI FDA approval for severe alopecia areata
In a significant development for the treatment of severe alopecia areata, Sun Pharmaceutical Industries Limited has announced that the U.S. Food and Drug Administration (FDA) ... Read More
Sun Pharma’s NDA for Deuruxolitinib garners FDA nod: A potential leap for alopecia areata patients
Sun Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their investigational drug, ... Read More
Pfizer gets LITFULO FDA approval for severe alopecia areata
Pfizer has announced that the US Food and Drug Administration (FDA) has granted approval to LITFULO (ritlecitinib) as a once-daily oral treatment for individuals aged ... Read More
Sun Pharma to acquire Concert Pharmaceuticals to bolster dermatology franchise
India-based Sun Pharmaceutical Industries (Sun Pharma) will acquire US-based Concert Pharmaceuticals for equity consideration of $576 million to strengthen its global dermatology franchise. Concert Pharmaceuticals ... Read More